NYSE - Nasdaq Real Time Price USD

Enovis Corporation (ENOV)

37.35
+0.78
+(2.13%)
At close: May 13 at 4:00:02 PM EDT
37.35
0.00
(0.00%)
After hours: May 13 at 5:17:21 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Matthew L. Trerotola CEO & Chairman 2.93M -- 1967
Mr. Phillip Benjamin Berry Senior VP & CFO 988.72k -- 1979
Mr. Bradley J. Tandy J.D. Senior VP & Chief Legal Officer 874.35k -- 1959
Ms. Patricia A. Lang Senior VP & Chief Human Resources Officer 896.34k -- 1959
Mr. Daniel A. Pryor Executive Vice President of Strategy & Business Development 1.13M -- 1968
Mr. John Kleckner VP, Controller & Chief Accounting Officer -- -- 1977
Mr. Kyle William Rose Vice President of Investor Relations -- -- --
Katie Sweet Vice President of Corporate Communication -- -- --
Mr. Tim Czartoski President of U.S. Surgical and Global Product & Enabling Technologies -- -- --
Mr. Davide Visentin President of Enovis International Surgical -- -- --

Enovis Corporation

2711 Centerville Road
Suite 400
Wilmington, DE 19808
United States
302 252 9160 https://www.enovis.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
7,367

Description

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Corporate Governance

Enovis Corporation’s ISS Governance QualityScore as of May 1, 2025 is 2. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 2; Compensation: 1.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 5, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC

Enovis Corporation Earnings Date

Recent Events

May 8, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 11, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

April 2, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 14, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 26, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

January 13, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 7, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 28, 2024 at 12:00 AM UTC

11-K: Annual report of employee stock purchase

June 26, 2024 at 12:00 AM UTC

S-8: Offering Registrations

Related Tickers